Indivior (LON:INDV) Stock Passes Above Fifty Day Moving Average - Time to Sell?

Key Points

• Indivior PLC's stock recently crossed above its 50-day moving average, reaching a high of GBX 1,264 ($16.76) before closing at GBX 1,238 ($16.41).
• The company has a market capitalization of £1.93 billion and a notable debt-to-equity ratio of -170.06, indicating significant leverage.
• Insider Juliet Thompson purchased 1,925 shares at an average cost of GBX 1,388 ($18.40), reflecting confidence in the company's future prospects.

Indivior PLC (LON:INDV - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 1,061.72 ($14.09) and traded as high as GBX 1,264 ($16.78). Indivior shares last traded at GBX 1,238 ($16.43), with a volume of 8,457,898 shares.

Indivior Stock Performance

The company has a fifty day moving average of GBX 1,077.72 and a 200 day moving average of GBX 894.32. The stock has a market cap of £1.93 billion, a P/E ratio of -1,026.48, a PEG ratio of -5.57 and a beta of 0.19. The company has a debt-to-equity ratio of -170.06, a current ratio of 0.83 and a quick ratio of 1.52.

Insider Transactions at Indivior

In other news, insider Juliet Thompson bought 3,850 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were purchased at an average cost of GBX 1,388 ($18.42) per share, with a total value of £53,438 ($70,929.12). 3.44% of the stock is currently owned by insiders.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.